Acepromazine (PromAce)

Acepromazine, commonly known by the brand name PromAce and often abbreviated as ace in veterinary practice, is a phenothiazine tranquilizer that has been used in veterinary medicine for decades. This medication produces dose-dependent sedation, reduces anxiety, and decreases spontaneous motor activity without providing true anesthesia or analgesia. Acepromazine has been a mainstay of veterinary sedation protocols due to its reliability, low cost, and long track record of use. In feline patients, acepromazine serves multiple purposes including pre-anesthetic sedation to reduce stress and anesthetic drug requirements, chemical restraint for examination or minor procedures, and management of anxiety or motion sickness.

The mechanism of action of acepromazine involves antagonism of dopamine receptors in the central nervous system, particularly within the basal ganglia and limbic system. This dopamine receptor blockade produces the characteristic calming and sedative effects of phenothiazine drugs. Additionally, acepromazine has anti-adrenergic effects that contribute to peripheral vasodilation and the drug's hypotensive properties. The drug also has antihistamine and anticholinergic activity at higher doses. These combined actions produce behavioral calming, reduced motor activity, and decreased responsiveness to environmental stimuli without loss of consciousness at typical doses. The onset of action following intramuscular injection is typically fifteen to thirty minutes, with effects lasting two to four hours.

Acepromazine is available in both injectable and oral formulations to accommodate different clinical applications. The injectable solution, typically at a concentration of ten milligrams per milliliter, can be administered intramuscularly, subcutaneously, or intravenously depending on the desired onset time and clinical situation. Oral tablets are available in various strengths for administration before travel or stressful events. The injectable formulation is most commonly used in clinical settings for pre-anesthetic sedation, while oral administration is convenient for home use under veterinary direction. Both formulations produce similar effects when appropriate doses are used, though injectable routes provide faster and more reliable onset.

The safety profile of acepromazine in cats requires consideration of its cardiovascular effects and certain limitations compared to newer sedative options. The drug's alpha-adrenergic blocking properties cause peripheral vasodilation and can result in significant hypotension, particularly in compromised patients or when combined with other cardiovascular depressants. Acepromazine lowers the seizure threshold and is generally avoided in patients with seizure disorders. The drug provides no analgesia and should not be relied upon for pain control. Despite these considerations, acepromazine remains useful in veterinary practice when appropriate patient selection and dosing guidelines are followed. Veterinary supervision is important to ensure safe use in individual patients.

The primary indication for acepromazine in feline patients is pre-anesthetic sedation to reduce patient anxiety, facilitate handling, and decrease the dose requirements of subsequent anesthetic drugs. Cats administered acepromazine before anesthesia are typically calmer, easier to restrain for intravenous catheter placement, and require lower doses of induction agents. This reduction in anesthetic drug requirements can improve cardiovascular stability during the anesthetic period. Pre-anesthetic sedation protocols commonly combine acepromazine with opioid analgesics to provide both sedation and pain control before surgical procedures. The routine use of pre-anesthetic sedation has become standard practice in veterinary anesthesia.

Chemical restraint for examination, sample collection, or minor procedures represents another common application for acepromazine. Cats that are anxious, fearful, or mildly fractious may become cooperative after acepromazine administration, allowing thorough physical examination, blood collection, radiography, or other diagnostic procedures. The drug does not provide sufficient sedation for painful procedures or for handling truly aggressive animals, but it can significantly reduce stress-related handling difficulties in appropriately selected patients. Understanding the limits of acepromazine sedation helps veterinary teams select patients who will benefit from this intervention.

Anxiety management for specific stressful events falls within acepromazine's indication profile. Travel anxiety, particularly for car or air travel, has traditionally been managed with oral acepromazine given before the journey. Veterinary visits themselves can be extremely stressful for some cats, and oral acepromazine given at home before the appointment can reduce this stress. Thunderstorm or noise phobias may be partially addressed with acepromazine, though the drug's sedative effects without anxiolysis may not fully address underlying fear. Current thinking has shifted toward alternative anxiolytic approaches for some of these applications, but acepromazine remains an option for appropriate cases.

Motion sickness prevention represents a historical indication for acepromazine based on its antiemetic properties derived from antihistamine and antidopaminergic effects. Cats prone to vomiting during car travel may benefit from acepromazine administration before trips. The sedation produced may also reduce the anxiety component of motion sickness in some animals. However, newer antiemetic options with fewer sedative effects have largely replaced acepromazine for this specific indication in many practices. The choice of motion sickness prevention strategy depends on whether sedation is desired or would be problematic for the particular situation.

Veterinary selection of acepromazine over other sedative options depends on the clinical goals, patient characteristics, and concurrent medications planned. Acepromazine's advantages include low cost, long track record, availability in injectable and oral forms, and reliable calming effects. However, newer sedative classes such as alpha-2 agonists offer advantages including reversibility, better sedation quality, and analgesic properties that acepromazine lacks. The veterinary team evaluates each case to determine the most appropriate sedation approach, considering factors such as patient health status, procedure planned, and recovery requirements.

Acepromazine dosing requires careful consideration of individual patient factors, as response to phenothiazine tranquilizers varies considerably between animals. The veterinary team determines appropriate doses based on patient temperament, health status, concurrent medications, and the level of sedation desired. Cat owners may administer oral acepromazine at home according to veterinary instructions, while injectable administration is performed in clinical settings. Understanding dosing principles helps owners safely use prescribed acepromazine and communicate effectively with their veterinary team.

Injectable acepromazine is most commonly administered intramuscularly or subcutaneously for pre-anesthetic sedation, with typical doses ranging from 0.01 to 0.1 milligrams per kilogram. The wide dose range reflects the significant individual variation in acepromazine response and the different levels of sedation required for various applications. Most practitioners use doses toward the lower end of this range, as acepromazine effects can be difficult to overcome if excessive sedation occurs. Intramuscular injection provides reliable absorption with onset in fifteen to thirty minutes. Subcutaneous administration may have slightly slower and more variable absorption. Intravenous administration produces faster onset but is less commonly used due to potential for hypotension.

Oral acepromazine tablets are prescribed for home administration before travel, veterinary visits, or other anticipated stressful events. Typical oral doses are similar to or slightly higher than injectable doses, generally 0.5 to 2 milligrams per cat depending on size and desired effect. The tablets should be given one to two hours before the anticipated stressful event to allow time for absorption and onset of effect. Administration with a small amount of food may improve tolerance and absorption. Cat owners should follow veterinary instructions precisely regarding dosing and timing, and should not adjust doses without consultation.

The duration of acepromazine effect typically ranges from two to four hours for the primary sedation, with residual effects potentially lasting longer. Peak effect occurs approximately one hour after intramuscular injection or one to two hours after oral administration. Recovery to normal behavior takes several hours, and cats should be monitored until fully recovered. There is no reversal agent for acepromazine, so excessive sedation must be managed supportively and allowed to resolve as the drug is metabolized. This lack of reversibility is one reason practitioners often use conservative doses.

Maximum dose limits exist for acepromazine to prevent excessive sedation and cardiovascular complications. Most references suggest maximum single doses of 3 milligrams total per cat, regardless of body weight, as larger cats do not necessarily require proportionally higher doses. Doses above this ceiling increase the risk of prolonged sedation and significant hypotension without improving sedation quality. Giant breed cats or those at the upper end of normal feline weights should still receive doses within the recommended maximum. The veterinary team establishes appropriate dose limits based on individual patient assessment.

Special considerations affect acepromazine dosing in various patient populations. Geriatric cats often require reduced doses due to decreased hepatic metabolism and increased sensitivity. Cats with cardiovascular disease, liver disease, or debilitation should receive minimal doses or alternative sedatives. Breed-specific sensitivities exist, with certain breeds requiring particular caution. Patient weight should be confirmed before dosing, with adjustments made for body condition. The goal is to use the minimum effective dose to achieve necessary sedation while minimizing adverse effect risk.

Acepromazine produces predictable side effects related to its pharmacological mechanisms, most of which are manageable with appropriate patient selection and dosing. Understanding expected effects helps veterinary teams anticipate and manage them appropriately. The drug's long track record provides extensive information about adverse effect profiles in various species including cats.

Cardiovascular effects are among the most significant concerns with acepromazine use. The drug's alpha-adrenergic blocking properties cause peripheral vasodilation, which can result in decreased blood pressure. In healthy patients at appropriate doses, this hypotensive effect is usually mild and well-tolerated. However, patients with compromised cardiovascular function, hypovolemia, or those receiving other cardiovascular depressants may experience significant hypotension requiring intervention. Reflex tachycardia may occur in response to blood pressure decreases. These cardiovascular effects are one reason acepromazine is used cautiously or avoided in debilitated patients.

Sedation is the intended effect of acepromazine, but excessive sedation can occur, particularly in sensitive individuals or when doses exceed patient requirements. Since no reversal agent exists for phenothiazine tranquilizers, excessive sedation must resolve through drug metabolism over several hours. Profound sedation can impair thermoregulation, requiring attention to environmental temperature during recovery. Cats may appear deeply sedated but still responsive to painful stimuli, as acepromazine provides no analgesia. This residual pain response should not be interpreted as inadequate sedation when the goal is simply tranquility rather than anesthesia.

Behavioral effects of acepromazine warrant consideration when selecting this drug for specific applications. While most cats become calmer and easier to handle, a subset may show paradoxical excitement or aggression, particularly if stimulated before full sedation develops. This paradoxical response is more common in excitable or fearful animals and can complicate handling attempts. Ideally, acepromazine is administered and the patient left undisturbed until sedation is established. The sedation produced may also unmask underlying aggression in some animals by reducing inhibitory behaviors while the animal retains capacity for defensive reactions.

Other adverse effects associated with acepromazine include protrusion of the third eyelid (nictitating membrane), which is common and generally harmless. Decreased tear production may occur, and eye lubrication may be warranted during prolonged sedation. Acepromazine lowers the seizure threshold, making it unsuitable for patients with seizure disorders. The drug can cause penile prolapse in male cats, though this is more commonly reported in horses. Temperature regulation impairment can lead to hypothermia, particularly in cool environments or during prolonged procedures. These effects are generally manageable with appropriate monitoring and supportive care.

Acepromazine is contraindicated in cats with known hypersensitivity to phenothiazine drugs. Cats that have experienced adverse reactions to acepromazine or related phenothiazine compounds should not receive this medication. Cross-reactivity between different phenothiazine drugs is possible, so previous reactions to any drug in this class warrant caution. Complete disclosure of any previous sedation or tranquilizer problems to the veterinary team helps identify patients with potential phenothiazine sensitivity.

Cardiovascular compromise represents a significant contraindication to acepromazine use due to the drug's hypotensive effects. Cats with hypovolemia, shock, dehydration, or cardiac disease are at increased risk for dangerous blood pressure decreases following acepromazine administration. The drug should be avoided in patients with uncompensated heart failure or those who are hemodynamically unstable. Even in stable cardiac patients, acepromazine should be used with great caution and at reduced doses. Alternative sedatives with less cardiovascular impact may be preferred for patients with cardiovascular concerns.

Seizure disorders constitute a contraindication for acepromazine because the drug lowers the seizure threshold. Cats with history of seizures, those receiving anticonvulsant therapy, or those with conditions predisposing to seizures should not receive acepromazine. The lowered seizure threshold can precipitate seizure activity in susceptible animals, potentially causing injury and complicating medical management. Alternative sedatives without epileptogenic properties should be selected for these patients. Complete medical history disclosure ensures appropriate drug selection.

Certain toxicities and specific clinical conditions represent additional contraindications. Organophosphate or carbamate toxicity is specifically listed as a contraindication, as acepromazine may enhance the toxicity of these compounds. Tetanus is traditionally listed as a contraindication due to concerns about enhanced muscle rigidity. Profound debilitation, severe anemia, or other conditions limiting physiological reserve may make acepromazine's cardiovascular effects more dangerous. Very young kittens have immature drug metabolism and may have unpredictable responses. Geriatric patients with significant organ dysfunction require careful evaluation before acepromazine use.

Acepromazine interacts significantly with other central nervous system depressants, which is the basis for its use in balanced pre-anesthetic protocols but also a source of potential adverse effects if not appropriately managed. Other sedatives, anesthetics, and opioids all have enhanced effects when combined with acepromazine. This synergy is intentionally utilized to reduce doses of individual drugs, but failure to account for these interactions can result in profound sedation, respiratory depression, or cardiovascular compromise.

Opioid analgesics are frequently combined with acepromazine in pre-anesthetic protocols, creating what is commonly called neuroleptanalgesia. This combination provides both sedation from the acepromazine and analgesia from the opioid, offering advantages over either drug alone. However, the combination produces greater cardiovascular and respiratory depression than either drug alone, requiring appropriate dose reductions of both components. Standard neuroleptanalgesic combinations use low doses of each drug to achieve their synergistic benefits while minimizing adverse effects.

Antihypertensive medications and other drugs affecting blood pressure interact with acepromazine's hypotensive effects. Cats receiving chronic antihypertensive therapy may experience enhanced blood pressure decreases with acepromazine. Similarly, anesthetic drugs with cardiovascular depressant effects have enhanced hypotensive potential when combined with acepromazine. Monitoring blood pressure when acepromazine is used in conjunction with these drugs helps identify and manage excessive hypotension. Dose adjustments of acepromazine or the concurrent medications may be necessary.

Certain drug classes should be used with caution or avoided in combination with acepromazine. Procaine and other drugs that can sensitize the heart to catecholamine-induced arrhythmias may pose increased risk when acepromazine is used, though this interaction is not commonly clinically significant. Anticonvulsant medications may have altered effects when combined with acepromazine's seizure threshold-lowering properties. Complete medication history including all prescription medications, over-the-counter products, and supplements should be disclosed to the veterinary team before acepromazine administration.

The timing of acepromazine relative to other medications affects interaction magnitude. When acepromazine is given as pre-medication before anesthesia, subsequent anesthetic induction agents should be dosed conservatively to account for the enhanced CNS depression. Monitoring during the period when multiple sedatives are active allows for early detection of excessive effects. The veterinary team plans drug administration sequences to optimize therapeutic effects while minimizing adverse interaction potential.

Acepromazine should be used with caution in any patient where hypotension would be particularly dangerous. The drug's alpha-adrenergic blocking effects cause peripheral vasodilation and can result in significant blood pressure decreases. Patients should be well-hydrated before acepromazine administration, and those with cardiovascular compromise should receive alternative sedatives or substantially reduced doses. Blood pressure monitoring is advisable when acepromazine is used in potentially compromised patients or in conjunction with other cardiovascular depressants.

Temperature regulation is impaired during acepromazine sedation, predisposing patients to hypothermia, particularly in cool environments. Cats should be maintained in warm environments during and after acepromazine administration. Supplemental heating may be necessary during procedures performed under acepromazine sedation. The vasodilation caused by acepromazine contributes to heat loss and further compromises temperature regulation. Recovery areas should be appropriately warmed, and patients should be monitored for hypothermia until fully recovered.

The lack of reversal agent for acepromazine necessitates conservative dosing and careful patient selection. Unlike some newer sedative classes with available antagonists, phenothiazine effects cannot be pharmacologically reversed and must resolve through drug metabolism. Excessive sedation can persist for many hours, potentially complicating patient care and recovery. This characteristic makes acepromazine unsuitable for situations requiring rapid return to normal function or where precise control over sedation duration is needed. Dose conservatively and allow sufficient time for recovery before discharge.

Aggressive or highly excited animals may not be adequately controlled with acepromazine and may exhibit paradoxical reactions. The drug should be given before handling when possible, allowing time for sedation to develop before stimulating the patient. Attempting to handle animals during the induction period, before sedation is established, can precipitate aggressive responses. Truly aggressive or feral cats typically require more potent sedative combinations rather than acepromazine alone. Patient temperament assessment helps predict likely response to acepromazine sedation.

Specific patient populations require additional precautions. Geriatric cats metabolize acepromazine more slowly and may be more sensitive to its effects, necessitating dose reductions. Cats with hepatic disease have impaired drug metabolism and require careful dose adjustment. Brachycephalic breeds may have airway concerns exacerbated by sedation. Giant breed cats should not receive doses exceeding recommended maximums regardless of body weight. Pre-procedure assessment identifies patients requiring modified protocols or alternative sedative approaches.

Acepromazine injectable solution and tablets should be stored at controlled room temperature, typically between fifteen and thirty degrees Celsius (59 to 86 degrees Fahrenheit), protected from light. The injectable formulation should be kept in its original packaging to protect from light exposure, which can cause degradation. Freezing should be avoided for the injectable solution. Both formulations should be stored in secure locations away from children and pets, as accidental ingestion can cause significant sedation and cardiovascular effects.

Injectable acepromazine solution should be inspected visually before each use. The solution is normally clear and colorless to slightly yellow. Any solution showing discoloration, cloudiness, precipitate, or particulate matter should not be used and should be disposed of appropriately. Multi-dose vials should be handled using aseptic technique to prevent contamination. Dating of opened vials according to facility protocols helps ensure timely use and appropriate disposal. The rubber stopper should be wiped with alcohol before each withdrawal.

Oral acepromazine tablets should be stored in their original container with child-resistant closure. The tablets should be protected from moisture and excessive heat. Cat owners prescribed acepromazine for home use should store the medication safely out of reach of children and pets. Any unused medication remaining after the prescribed course or expiration date should be disposed of properly rather than kept for potential future use without veterinary consultation.

Proper disposal of unused acepromazine follows standard pharmaceutical waste guidelines. While acepromazine is not a controlled substance, unused medication should not be discarded in household trash where it could be accessed by children, pets, or wildlife. Many communities have pharmaceutical take-back programs for safe disposal. Alternatively, medications can often be mixed with undesirable substances and placed in sealed containers for trash disposal according to FDA guidelines. Veterinary facilities dispose of pharmaceutical waste according to applicable regulations. Empty vials and used syringes from injectable acepromazine are disposed of in appropriate sharps containers.

Acepromazine response can vary among cat breeds, though individual variation within breeds is often more significant than breed differences per se. The veterinary team considers breed alongside other patient factors when planning sedation protocols. Certain breed-associated conditions may influence the safety or appropriateness of acepromazine for specific patients, warranting attention during pre-sedation assessment.

Giant and large breed cats may paradoxically require lower total acepromazine doses than might be expected based on body weight. Maximum dose ceilings apply regardless of patient size, as larger cats do not necessarily require proportionally higher doses to achieve adequate sedation. Maine Coons and other large breeds should still receive doses within recommended limits. Additionally, larger breeds may have increased prevalence of certain cardiac conditions that affect acepromazine safety. Breed-specific cardiac screening may be appropriate before elective sedation procedures.

Brachycephalic breeds including Persians, Himalayans, and Exotic Shorthairs have airway anatomy that can be compromised by sedation effects. While acepromazine is generally safe in these breeds, the sedation and potential muscle relaxation can exacerbate airway resistance. Monitoring for respiratory effort and airway patency during sedation is particularly important in brachycephalic patients. Recovery supervision should continue until normal airway protective mechanisms are restored. These considerations apply to any sedative use in brachycephalic breeds, not specifically to acepromazine.

Individual sensitivity to acepromazine varies considerably within any breed, and previous experience with sedation in an individual patient provides valuable guidance for future sedation events. Cats that have shown good response to specific acepromazine doses may be expected to respond similarly to future doses. Conversely, cats that have shown excessive sensitivity or paradoxical reactions should have this documented for future reference. First-time acepromazine use warrants careful monitoring to assess individual response. Owner observations about previous sedation experiences provide useful information for protocol planning.

Alpha-2 adrenergic agonists including dexmedetomidine and medetomidine represent the primary alternative sedative class to acepromazine in veterinary practice. These drugs provide more profound and reliable sedation than acepromazine, along with analgesic properties that phenothiazines lack. A major advantage is the availability of specific reversal agents (alpha-2 antagonists) allowing rapid recovery when needed. However, alpha-2 agonists have their own contraindications including cardiovascular effects different from but not necessarily less significant than acepromazine. The choice between sedative classes depends on patient factors, procedure requirements, and recovery needs.

Benzodiazepines including midazolam and diazepam offer another alternative sedative approach with distinctly different characteristics. These drugs provide anxiolysis and muscle relaxation with minimal cardiovascular effects, making them suitable for compromised patients. However, benzodiazepines alone often provide inadequate sedation in healthy cats and may cause paradoxical excitation. They are most commonly used in combination with other sedatives or as components of anesthetic protocols rather than as sole sedatives. Reversal agents are available for benzodiazepines, offering controllability that acepromazine lacks.

Within the phenothiazine class, several other drugs exist with similar mechanisms but varying characteristics. Chlorpromazine was one of the original phenothiazine tranquilizers but is now rarely used in veterinary practice. Promazine is occasionally used as an alternative to acepromazine. These related drugs share the cardiovascular effects and lack of reversibility characteristic of phenothiazines. Acepromazine remains the most commonly used phenothiazine in veterinary medicine due to its established track record and predictable effects.

Complementary medications are frequently combined with acepromazine to create balanced sedation or pre-anesthetic protocols. Opioid analgesics combined with acepromazine provide both sedation and pain control. Anticholinergics such as atropine or glycopyrrolate may be added to prevent bradycardia or excessive salivation during subsequent anesthesia. These combination protocols allow lower doses of individual drugs while achieving optimal sedation characteristics. The specific combination selected depends on the clinical situation and individual patient requirements.